# A Phase II Study of AT7519M, a CDK Inhibitor, in Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia

> **NCT01627054** · PHASE2 · COMPLETED · sponsor: **NCIC Clinical Trials Group** · enrollment: 7 (actual)

## Conditions studied

- Chronic Lymphocytic Leukemia

## Interventions

- **DRUG:** AT7519M

## Key facts

- **NCT ID:** NCT01627054
- **Lead sponsor:** NCIC Clinical Trials Group
- **Sponsor class:** NETWORK
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-08-27
- **Primary completion:** 2014-03-21
- **Final completion:** 2015-02-13
- **Target enrollment:** 7 (ACTUAL)
- **Last updated:** 2023-08-04

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01627054

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01627054, "A Phase II Study of AT7519M, a CDK Inhibitor, in Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT01627054. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*